← Back to all trials
Completed
NCT07704684
Assess Sacubitril/Allisartan and Amlodipine in Patients With Essential Hypertension Uncontrolled With Amlodipine
Conditions: Essential Hypertension
Sex: All
Ages: 18 Years – 75 Years
Healthy volunteers: No
Phase: PHASE3
Enrollment: 376
Sponsor: Shenzhen Salubris Pharmaceuticals Co., Ltd.
Location: Peking University First Hospital Beijing Beijing Municipality
Summary
The main objective of the study will be to assess the efficacy and safety of Sacubitril/Allisartan (240mg) and Amlodipine (5mg) in patients with essential hypertension uncontrolled after 4-week treatment with Amlodipine (5mg).
Eligibility Criteria
Inclusion Criteria:
1. Patients 18-75 years old.
2. Confirmed diagnosis of essential hypertension.
3. Patients who meet one of the following criteria when screening:
A. Treatment-naive patients (newly diagnosed essential hypertension, or patients with a prior hypertension history who have not taken any antihypertensive medication for at least 4 weeks prior to screening): mean seated systolic blood pressure (msSBP) ≥150 mmHg and \
Source: ClinicalTrials.gov (NCT07704684). StuddyBuddy aggregates publicly available trial information.
